Project description
Broad-spectrum solutions for emerging viruses
Emerging viruses, such as those responsible for the COVID-19 pandemic and the Ebola epidemic, pose a critical threat to global health and economic stability. Factors like climate change are expected to exacerbate the frequency and severity of these outbreaks. Addressing these challenges requires innovative strategies to combat diseases for which effective countermeasures are lacking. Current priority pathogens identified by the World Health Organization underscore the urgency of this mission. With this in mind, the EU-funded VIGILANT project will develop broad-spectrum antivirals targeting the Sec61 channel and virus-activating proteases. With expertise in inhibitor development and protein analysis, it aims to deliver safe solutions ready for clinical evaluation, advancing the fight against epidemic-prone viruses.
Objective
The VIGILANT consortium is dedicated to tackling the global threat posed by emerging viruses, exemplified by the COVID-19 pandemic and the Ebola epidemic in Western Africa. These events have emphasized the profound impact of such viruses on human health and economic stability. Moreover, anthropogenic factors, notably climate change, will result in an increase in the frequency of outbreaks caused by these viruses in the future. To address this vulnerability, the VIGILANT consortium pursues the development of antivirals with broad-spectrum activity. Pioneering research conducted by the consortium has identified the inhibition of the Sec61 channel and virus-activating host proteases as a promising strategy.
The consortium's efforts are centered on addressing priority diseases defined by the World Health Organization due to their epidemic potential and the lack of countermeasures. Thus, the VIGILANT consortium aims to provide new insights into the protease dependence of emerging viruses, including Ebola virus, Marburg virus, Nipah virus, Zika virus, and Chikungunya virus. Furthermore, VIGILANT will develop inhibitors of the virus-activating proteases furin and cathepsin B/L that are safe and exert broad and potent antiviral activity in cell culture and animal models and are thus ready for clinical evaluation. Furthermore, VIGILANT will devise inhibitors targeting Sec61 and will determine breadth of antiviral activity and potential resistance mechanisms.
To achieve these ambitious goals, VIGILANT has assembled an array of partners with unique resources and expertise. These partners have demonstrated success in inhibitor development, protease profiling, protein structure determination, and analysis of antivirals. By leveraging their collective capabilities, the VIGILANT consortium aims to provide important insights into ER import and activation of viral glycoproteins and to bring about a quantum leap in pandemic preparedness – the development of broad-spectrum antiviral
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences microbiology virology
- medical and health sciences health sciences infectious diseases RNA viruses ebola
- medical and health sciences health sciences public health epidemiology pandemics
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antivirals
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.2.1 - Health
MAIN PROGRAMME
See all projects funded under this programme -
HORIZON.2.1.5 - Tools, Technologies and Digital Solutions for Health and Care, including personalised medicine
See all projects funded under this programme -
HORIZON.2.1.4 - Infectious Diseases, including poverty-related and neglected diseases
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-RIA - HORIZON Research and Innovation Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-HLTH-2024-DISEASE-08
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
37077 GOTTINGEN
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.